1. Academic Validation
  2. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

  • J Exp Med. 1994 Jul 1;180(1):347-52. doi: 10.1084/jem.180.1.347.
Y Kawakami 1 S Eliyahu K Sakaguchi P F Robbins L Rivoltini J R Yannelli E Appella S A Rosenberg
Affiliations

Affiliation

  • 1 Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Abstract

Four melanoma proteins, MART-1, gp100, Tyrosinase, and tyrosinase-related protein-1 (gp75) were evaluated for recognition by HLA-A2-restricted melanoma-specific cytotoxic T lymphocytes (CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 different patients. 9 of 10 TIL recognized MART-1, 4 recognized gp100 (including 3 that also recognized MART-1), but none of the TIL recognized Tyrosinase or gp75. Based on the known HLA-A2.1 peptide binding motifs, 23 Peptides from MART-1 were synthesized in an attempt to identify the epitopes recognized by TIL. Three Peptides were recognized by TIL when pulsed on T2 target cells. One of the 9-mer Peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis. This peptide was recognized by 9 of 10 HLA-A2-restricted melanoma-specific CTLs. Therefore, this peptide appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.

Figures
Products